-
Liraglutide and the Brain–Kidney AVP Axis
2026-10-07
Greenwood and colleagues combine clinical sampling, rat pituitary proteomics, phosphoproteomics, an AVP luciferase assay, and renal signaling analysis to investigate how liraglutide affects fluid homeostasis. The study identifies reduced circulating arginine vasopressin, sex- and time-dependent synaptic phosphorylation, and downstream aquaporin 2 changes, while also defining important limits on causal and translational interpretation.
-
Neutrophil Isolation as a Translational Decision
2026-10-07
Recent hepatocellular carcinoma research positions neutrophils as active therapeutic targets rather than passive bystanders. This thought-leadership analysis connects that finding with activation-conscious mouse neutrophil isolation, emphasizing evidence boundaries, study design strategy, and the translational value of high-purity cell preparations.
-
Captopril, ACE Inhibition, and Bradykinin Evidence
2026-10-06
This evidence-focused overview separates established Captopril pharmacology from findings in a guinea pig ileum study that examined bradykinin B2 receptors, not Captopril. It explains the study’s principles, design, evidence strength, interpretation, translational scope, and key limitations.
-
CYR61, Migrasomes, and Irradiated BMSC Repair
2026-10-06
A 2025 study identifies CYR61-containing migrasomes as a potential mechanism for restoring migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells. The findings connect CYR61–integrin αvβ3 signaling with ERK activation, while also highlighting the limits of translating an in vitro mechanism into osteoradionecrosis treatment.
-
(+)-Bicuculline: GABAA Antagonist Overview
2026-10-05
A concise, source-limited overview of (+)-Bicuculline (SKU N1592) as a research-use GABAA receptor antagonist. No matched paper evidence was available for independent assessment of mechanisms, outcomes, or performance.
-
Phenothiazines, ROS, and Autophagy in Macrophages
2026-10-04
Qiu et al. report that phenothiazines strengthen macrophage antibacterial activity through coordinated increases in reactive oxygen species, lysosomal activity, and autophagy. The study supports a host-directed therapy framework, while its mechanistic and translational conclusions remain bounded by the tested compounds, infection model, and available evidence.
-
Phalloidin B7678: Product Overview
2026-10-03
Phalloidin B7678 is a supplier-listed cyclic heptapeptide toxin associated with F-actin binding and actin filament stabilization. No matched paper evidence was provided, so performance, efficacy, and application-specific conclusions cannot be independently assessed.
-
Targeted Amikacin Delivery into Granulomas
2026-10-02
The reference study developed a dendritic-cell delivery strategy that transported fluorescently labeled amikacin into Mycobacterium avium granulomas in infected mice. Its main contribution is proof of organism-directed localization, while therapeutic efficacy, long-term safety, and clinical translation remain to be established.
-
Elobixibat Hydrate: Translational IBAT Strategy
2026-10-01
A mechanistic and strategic guide to using Elobixibat hydrate as a selective ileal bile acid transporter inhibitor for gastrointestinal, metabolic, and translational research.
-
AZD1480 JAK2 Inhibitor Workflow Guide
2026-10-01
Build mechanism-first cancer assays with AZD1480 to resolve how tumor-intrinsic JAK2/STAT3 signaling supports survival under immune and metabolic stress. The workflow combines phospho-signaling, viability, co-culture, and combination-treatment readouts for myeloma and solid-tumor research.
-
MK0787 Versus Cefoperazone: 1982 Evidence
2026-09-30
This comparative study evaluated N-formimidoyl thienamycin (MK0787) across resistant and difficult-to-treat bacterial isolates, using both MIC and bactericidal endpoints. Its findings positioned MK0787 as especially potent against Pseudomonas aeruginosa and Acinetobacter spp., while showing that activity varied substantially by organism and comparator, including Cefoperazone.
-
5-hme-dCTP: Reliable Epigenetic Assays
2026-09-30
Learn how 5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate), SKU B8113, can support controlled DNA hydroxymethylation workflows linked to proliferation, cytotoxicity, and gene-expression studies. The article emphasizes polymerase compatibility, handling, interpretation, and evidence-based product selection.
-
Rapamycin (Sirolimus) Workflow for mTOR Studies
2026-09-29
Build a practical Rapamycin workflow that connects mTOR inhibition with translation control, cell-cycle biology, immunology, and mitochondrial disease models. The guide emphasizes dose design, pathway-resolved readouts, and troubleshooting for rapamycin-resistant cap-dependent translation.
-
Atrial Natriuretic Peptide: Applied Research Guide
2026-09-29
Learn how to use rat Atrial Natriuretic Peptide as a controlled perturbation tool for vascular, renal, and adipose assays. This guide connects practical formulation and dosing workflows with the reference study’s rigorous rescue-design logic while separating established cardiovascular applications from exploratory neuroinflammatory hypotheses.
-
Mecamylamine Hydrochloride for Circuit Research
2026-09-28
Use mecamylamine to test whether nicotinic acetylcholine receptors contribute to a gut–vagus–brain response—not to assume that a microbiome finding is already a drug mechanism. This workflow connects receptor-level antagonism with practical controls, dose selection, and interpretation limits for neuropsychiatric disorder research.